Search Result for : Department Of Pharmaceuticals

The Dollar Business Bureau A leading Indian pharmaceuticals company Aurobindo Pharma has said that it would widen its product portfolio in the American market while planning to enter new markets in the Europe, a part of the company’s growth strategy in the coming 3-4 years. In the US market, Aurobindo Pharma plans to widen its portfolio through faster growth in OTC, injectable and higher complexity products, the company said in a presentation to investors. However, in European market, the company plans to enhance its presence in new geographies like Czech Republic and Poland, in addition to strengthening its position in the existing markets of Germany, France, Spain, Netherlands and the UK. Aurobindo Pharma is the 6th largest generic company by volume in the US, ...

Source: PTI The government is working on several steps, including removing duty anomalies, to boost medical devices manufacturing sector and make it a $50 billion industry in the next five years, a top official on Friday said. Secretary in the Department of Pharmaceuticals, V K Subburaj, said that soon recommendations will be made to rectify the inverted duty structure for the growing medical devices sector. He said departments of health and pharmaceuticals along with the Department of Industrial Policy and Promotion (DIPP) is working on the matter and soon they will make recommendations to the revenue department on the issue. An inverted duty structure impacts domestic industry adversely as manufacturers have to pay a higher price for raw material in terms ...

The Dollar Business Bureau In a move to strengthen the Indian medical devices industry, the Department of Pharmaceuticals (DoP) has come up with a National Medical Device Policy (NMDP) 2015, aimed at promoting ‘Make in India’ in this industry by reducing dependence on imports. A draft was issued by DoP on June 3, 2015, seeking comments prior to implementation. The policy intends to set up a strong base for manufacturing of medical devices in India, especially for the affordable variety. It comes during a time when the aforesaid industry is dependent on imports from developed nations. According to DoP estimates, global market for medical devices is valued at around $20 billion, with US leading the supply pack with a 45% share, ...

The Dollar Business Bureau The bio-services sector which is currently valued at US$ 5-6 billion is set to increase to US$ 50 billion soon and we should be prepared to meet this growth. V K Subburaj, Secretary, Department of Pharmaceuticals, Ministry of Chemicals & Fertilisers, made the above statement at a round-table meeting on ‘Unleashing Opportunities in Bio-Services Including Contract Research & Manufacturing’, in New Delhi, on Friday. Stating that India makes pharmaceutical products worth US$ 30 billion every year and is a leading producer of generics, the Secretary expressed hope that the bio-pharmaceuticals will take over the sector in future. Speaking at the meet, the Secretary further stated that the conducive atmosphere for growth has been missing in ...

 The Dollar Business Bureau The Union Minister of Chemicals & Fertilizers Ananth Kumar on Wednesday called for the incentivisation of the Bulk Drugs sector so as to take on the challenges from cheap imports. Referring to the sector as a backbone of the Indian Pharmaceutical Industry, the Minister said, “Over-dependence on imports from one country for bulk drugs is detrimental to the country’s interest and hence, paradigm shift is necessary.” Speaking at the launch ceremony of “2015 – Year of Active Pharmaceutical Ingredients”, the Minister said that the decisions to be taken by the Ministry will make India self-sufficient in the Bulk Drugs sector. In this regard, he informed that the government has set up the Katoch ...